信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

交易中 02-09 11:51:23 EST

5.22

-0.02

-0.38%

最高5.24	最低5.08	成交量18.20万
今开5.21	昨收5.24	日振幅3.15%
总市值2.50亿	流通市值1.79亿	总股本4,788万
成交额93.83万	换手率0.53%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":5.22,"timestamp":1770655876510,"preClose":5.24,"halted":0,"volume":182040,"delay":0,"changeRate":-0.003816793893129859,"floatShares":34233044,"shares":47884104,"eps":0.190275,"marketStatus":"交易中","change":-0.02,"latestTime":"02-09 11:51:23 EST","open":5.21,"high":5.2448,"low":5.08,"amount":938298.0196319999,"amplitude":0.03145,"askPrice":5.23,"askSize":240,"bidPrice":5.21,"bidSize":110,"shortable":3,"etf":0,"ttmEps":0.190275,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":5.24,"dividendRate":0.034483,"preHourTrading":{"tag":"盘前","latestPrice":5.21,"preClose":5.24,"latestTime":"09:29 EST","volume":32,"amount":166.409984,"timestamp":1770647399917,"change":-0.03,"changeRate":-0.005725,"amplitude":0.001908},"postHourTrading":{"tag":"盘后","latestPrice":5.24,"preClose":5.24,"latestTime":"18:42 EST","volume":1355,"amount":7100.2,"timestamp":1770421322245,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.500671,"impliedVol":0.7506,"impliedVolPercentile":0.498},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2610503880","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”III期临床试验完成受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2610503880","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610503880?lang=zh_cn&edition=full","pubTime":"2026-02-09 06:15","pubTimestamp":1770588951,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的国家1类创新药维特柯妥拜单抗“CLDN18.2 ADC”正在开展用于治疗三线及以上CLDN18.2阳性的局部晚期或转移性胃及胃食管交界部腺癌的III期注册临床试验，已顺利完成患者入组。其中，LM302是全球首款完成注册III期临床试验入组的CLDN18.2 ADC药物。该研究表明，LM302联合治疗方案在CLDN18.2阳性患者中展现出显著的抗肿瘤活性和可管理的安全性特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK1191","IE00BZ08YS42.EUR","BK4231","01177","IE00BZ08YT58.USD","III","HK0000165453.HKD","BK1589","BK1515","ADC","IE00BZ08YR35.GBP","BK4080","BK4134"],"gpt_icon":0},{"id":"2609321873","title":"AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609321873","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609321873?lang=zh_cn&edition=full","pubTime":"2026-02-05 14:52","pubTimestamp":1770274343,"startTime":"0","endTime":"0","summary":"专注于哮喘治疗的AI生物科技公司Generate Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["III","BK4585","BK4134","159837","LABU","BK4588"],"gpt_icon":0},{"id":"2608359175","title":"广生堂(300436.SZ)：奈瑞可韦GST-HG141完成III期临床试验受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608359175","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608359175?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:43","pubTimestamp":1770194609,"startTime":"0","endTime":"0","summary":"智通财经APP讯，广生堂(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司的在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入组578例。本次GST-HG141完成III期临床试验全部受试者入组后，尚需按照已制定临床方案和要求继续推进临床试验，并经国家药品审评部门注册审批通过后方可上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","300436","BK0239","GST","III"],"gpt_icon":0},{"id":"2608289128","title":"卓创资讯：大宗商品价格波动加剧提升市场对专业信息服务的需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2608289128","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608289128?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:44","pubTimestamp":1770104687,"startTime":"0","endTime":"0","summary":"证券之星消息，卓创资讯 02月03日在投资者关系平台上答复投资者关心的问题。卓创资讯作为国内领先的大宗商品信息服务企业，始终专注于市场数据监测、价格评估及行业分析。当前大宗商品及贵金属价格波动加剧，客观上提升了市场对专业信息服务的需求，尤其可能吸引更多金融机构等非产业客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260203/31994528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["161715","BK0231","000979.SH","BK4134","301299","III"],"gpt_icon":0},{"id":"2608694859","title":"软件和信息服务业成江苏南京首个万亿级产业集群","url":"https://stock-news.laohu8.com/highlight/detail?id=2608694859","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608694859?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:22","pubTimestamp":1770020520,"startTime":"0","endTime":"0","summary":"中新社南京2月2日电 南京市工业和信息化局2日发布消息，根据中国工业和信息化部软件业运行快报，江苏南京2025年软件业务收入规模约为10200亿元，同比增长16.7%。由此，软件和信息服务业成为南京首个万亿级产业集群。早在2001年，南京出台了软件和信息服务业发展专项政策，系统布局发展软件产业。据统计，2025年南京入库人工智能(软件)招商项目326个，其中投资额亿元以上项目90个、高能级项目21个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-02/doc-inhkmfsh8088853.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-02/doc-inhkmfsh8088853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"gpt_icon":0},{"id":"2608880406","title":"诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608880406","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608880406?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:50","pubTimestamp":1769993437,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月2日，诺诚健华官微宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组，总共入组383例患者。这一里程碑标志着ICP-488治疗银屑病取得重大临床进展，有望为银屑病患者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照，旨在评价ICP-488单药治疗中重度斑块状银屑病成人患者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638037294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638037294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","III","688428","BK4134","BK1161","BK0239"],"gpt_icon":0},{"id":"2607790083","title":"歌礼制药-B(01672)：同类首创每日一次口服FASN抑制剂地尼法司他(ASC40)治疗痤疮的III期开放标签研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2607790083","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607790083?lang=zh_cn&edition=full","pubTime":"2026-01-29 18:56","pubTimestamp":1769684198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，同类首创、每日一次口服小分子脂肪酸合成酶抑制剂地尼法司他在中重度寻常性痤疮患者中的III期开放标签研究取得积极顶线结果。这240例患者均接受了40周的每日一次地尼法司他治疗，且此前均接受过12周的地尼法司他或安慰剂治疗。地尼法司他 显示出良好的安全性和耐受性特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1161","BK1191","BK4134","BK1515","01672","III","BK1574"],"gpt_icon":0},{"id":"2605316104","title":"新股消息 | 普祺医药递表港交所 核心产品普美昔替尼凝胶已完成III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2605316104","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605316104?lang=zh_cn&edition=full","pubTime":"2026-01-22 07:20","pubTimestamp":1769037657,"startTime":"0","endTime":"0","summary":"普美昔替尼凝胶：全球首款用于治疗特应性皮炎的JAK抑制剂凝胶，公司已就其完成成人及12至17岁青少年特应性皮炎适应症的III期临床试验，有待提交新药上市申请。普美昔替尼鼻喷雾剂：全球首款用于治疗季节性过敏性鼻炎的临床阶段JAK抑制剂鼻喷雾剂，现正处于针对成年人SAR适应症的III期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4134","HEXmain","159938","BK1574","III","09939","BK1161"],"gpt_icon":0},{"id":"2605435278","title":"百时美施贵宝 (BMS) CAR-T疗法启动III期临床，治疗自免疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2605435278","media":"细胞治疗前沿","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605435278?lang=zh_cn&edition=full","pubTime":"2026-01-21 09:53","pubTimestamp":1768960424,"startTime":"0","endTime":"0","summary":"近日，美国临床试验收录网显示，百时美施贵宝的 CD19 CAR-T 细胞疗法 Zola-cel启动了首个 Ⅲ 期临床试验，治疗活动性系统性硬化症。Zola-cel是BMS基于NEX-T平台开发的一款CD19 CAR-T细胞疗法，于2020年进入临床阶段。2019年，BMS以740亿美元完成对Celgene的收购，借此将两款关键CAR-T疗法Breyanzi与Abecma纳入其产品管线，正式踏入细胞治疗领域。BMS积极布局，不断强化其在下一代细胞治疗领域的战略纵深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2125154778.USD","LU2242652126.USD","LU0306806265.USD","LU0985481810.HKD","LU2133065610.SGD","LU1989771016.USD","LU1718418525.SGD","LU2360032135.SGD","LU0061475181.USD","LU0225284248.USD","LU1323610961.USD","LU1868836591.USD","CAR","LU1291159041.SGD","LU0114720955.EUR","BMY","BMS","LU1670711040.USD","LU1868836914.USD","LU1571399168.USD","IE00BFXG1179.USD","LU1261432733.SGD","BK4007","LU1670711123.USD","LU0225771236.USD","BK4585","LU0882574055.USD","LU0321505439.SGD","IE00BJJMRZ35.SGD","LU1868837136.USD","BK4134","IE00BSNM7G36.USD","BK4559","BK4534","BK4581","LU0096364046.USD","IE0002141913.USD","LU0306807586.USD","LU1670710661.SGD","LU2125154935.USD","LU0321505868.SGD","LU0267386448.USD","LU0868494617.USD","LU1868836757.USD","BK4588","IE00BFTCPJ56.SGD","LU1032466523.USD","BK4532","III","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2604929562","title":"因欠费被暂停III期试验，康乐卫士困境何时解？","url":"https://stock-news.laohu8.com/highlight/detail?id=2604929562","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604929562?lang=zh_cn&edition=full","pubTime":"2026-01-18 07:08","pubTimestamp":1768691280,"startTime":"0","endTime":"0","summary":"　　近日，康乐卫士发布公告称，公司收到山西省、江苏省两省疾控中心发来的函件：由于临床试验经费短缺，无法继续开展后续妇科访视工作，两省决定暂停其三价及九价HPV疫苗女性适应证的III期临床试验。　　有券商医药行业分析师对21世纪经济报道记者表示，康乐卫士此次因临床试验经费欠付导致III期试验被暂停，凸显了创新型疫苗企业在临床后期阶段的资金脆弱性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-18/doc-inhhsmvi8105223.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-18/doc-inhhsmvi8105223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"gpt_icon":0},{"id":"2604446209","title":"和黄医药涨逾5% SACHI III期研究结果于《柳叶刀》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2604446209","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604446209?lang=zh_cn&edition=full","pubTime":"2026-01-16 23:17","pubTimestamp":1768576666,"startTime":"0","endTime":"0","summary":"周五，和黄医药涨逾5%，报16.12美元。消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼和奥希替尼的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体酪氨酸激酶抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116232631a72389bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116232631a72389bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4531","BK4007","BK4134","HCM","BK4588","III","BK4585"],"gpt_icon":0},{"id":"2603492998","title":"百利天恒股东OAP III(HK)Limited拟减持不超1%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603492998","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603492998?lang=zh_cn&edition=full","pubTime":"2026-01-16 19:54","pubTimestamp":1768564470,"startTime":"0","endTime":"0","summary":"1月16日，百利天恒（688506）发布公告，股东OAPIII(HK)Limited因自身资金需求，计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持不超过413万股公司股份，占公司总股本的1%。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622097950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","III","688506","02615","BK4134","91194"],"gpt_icon":0},{"id":"2603554869","title":"港股异动 | 和黄医药(00013)再涨超4% 月内累涨逾两成 SACHI III期研究结果于《柳叶刀》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2603554869","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603554869?lang=zh_cn&edition=full","pubTime":"2026-01-16 11:03","pubTimestamp":1768532615,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药再涨超4%，月内累计涨幅超20%。消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼和奥希替尼的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体酪氨酸激酶抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HCM","00013","BK1587","III","BK4585","BK4531","BK1588","BK4007","BK1191","BK4134"],"gpt_icon":0},{"id":"1135602262","title":"信息服务集团预测全年托管服务收入将增长2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135602262","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135602262?lang=zh_cn&edition=full","pubTime":"2026-01-15 23:07","pubTimestamp":1768489628,"startTime":"0","endTime":"0","summary":"信息服务集团最新发布的全年展望显示，其托管服务业务预计将实现2.1%的营收增长。这一预测反映了公司对市场需求的审慎评估与战略布局的稳步推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","III"],"gpt_icon":0},{"id":"2603662471","title":"和黄医药盘中涨超3% SACHI III期研究结果于《柳叶刀》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2603662471","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603662471?lang=zh_cn&edition=full","pubTime":"2026-01-15 10:40","pubTimestamp":1768444800,"startTime":"0","endTime":"0","summary":"　　和黄医药盘中涨超3%，截至发稿，股价上涨2.39%，现报23.98港元，成交额7741.10万港元。　　据和黄医药官微消息，1月14日，和黄医药宣布SACHI III期研究的结果于《柳叶刀 》发表。　　据介绍，赛沃替尼是一种强效、高选择性的口服MET TKI，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-15/doc-inhhiyxt4368442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134","00013","BK1587","BK4585","HCM","BK4588","BK1191","BK1588","BK4531","BK4007"],"gpt_icon":0},{"id":"2603628850","title":"艾美疫苗(06660)：迭代工艺高效价人二倍体狂犬疫苗完成III期临床现场工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2603628850","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603628850?lang=zh_cn&edition=full","pubTime":"2026-01-15 07:09","pubTimestamp":1768432155,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾美疫苗 发布公告，集团研发的迭代工艺高效价人二倍体狂犬疫苗，目前III期临床现场工作已顺利完成。动物试验表明，集团人二倍体狂犬疫苗免疫后可产生高保护水平的抗体，在同一剂量条件下，集团人二倍体狂犬疫苗效价，显着高于已上市的人二倍体狂犬疫苗。集团已建设完全满足国际化标准的迭代工艺高效价人二倍体狂犬疫苗车间，并已完成商业化规模的三期临床试验样品的生产，具备该产品规模化生产的能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","III","159646","BK4134","06660"],"gpt_icon":0},{"id":"2603253613","title":"百时美施贵宝宣布评估玛伐凯泰治疗青少年有症状的梗阻性肥厚型心肌病（oHCM）的III 期临床试验SCOUT-HCM取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2603253613","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603253613?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:55","pubTimestamp":1768391700,"startTime":"0","endTime":"0","summary":"SCOUT-HCM 的阳性研究结果展现了玛伐凯泰有望成为首个用于青少年 oHCM 患者的心肌肌球蛋白抑制剂。青少年oHCM严重损害健康，主要临床表现与运动耐量下降相关。在欧盟，玛伐凯泰获批用于治疗有症状的NYHA心功能分级II-III级的梗阻性肥厚型心肌病成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4863243_ZH63243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1868837300.USD","LU1093756168.USD","LU0225771236.USD","LU1868837136.USD","LU1291159041.SGD","IE00BFXG1179.USD","LU2242646821.SGD","LU0114720955.EUR","LU1571399168.USD","LU1718418525.SGD","BMY","LU0061475181.USD","LU1868836914.USD","BK4559","BK4588","LU0096364046.USD","IE00BJT1NW94.SGD","LU0306806265.USD","LU1670711123.USD","IE0009355771.USD","LU1868836591.USD","LU0868494617.USD","LU2125154935.USD","LU0456855351.SGD","LU0985481810.HKD","IE00B2B36J28.USD","LU1989771016.USD","LU0306807586.USD","BK4134","LU1670710588.SGD","III","IE00BJJMRZ35.SGD","LU0321505439.SGD","LU0321505868.SGD","LU1430594728.SGD","LU1261432733.SGD","BK4585","BK4534","LU1585245621.USD","IE00BSNM7G36.USD","IE0002141913.USD","LU1670710661.SGD","LU0237698245.USD","LU0267386448.USD","LU1074936037.SGD","HCM","LU1323610961.USD","LU0225284248.USD","LU2242652126.USD","LU1093756325.SGD"],"gpt_icon":0},{"id":"2603439618","title":"阿斯利康AZD0486启动III期临床 适应症为新诊断的老年或不适合化疗的大B细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2603439618","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603439618?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:03","pubTimestamp":1768384980,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，AstraZeneca AB/阿斯利康全球研发（中国）有限公司/AstraZeneca Nijmegen B.V.的AZD0486在新诊断为大B细胞淋巴瘤的老年或不适合化疗的受试者中的多中心、开放性、随机III期临床试验已启动。本次试验药AZD0486的剂型、用法用量信息未公示。AZD0486为生物制品，适应症为新诊断的老年或不适合化疗的大B细胞淋巴瘤。大B细胞淋巴瘤是常见的非霍奇金淋巴瘤亚型，进展快，老年或不耐受化疗患者预后较差，需更安全有效的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114190129a4c2fc89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114190129a4c2fc89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4134","BK4007","LU0320765992.SGD","LU0109394709.USD","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","BK4585","BK4588","III","LU2417539215.USD","LU0889565916.HKD","AZN","BK4568","LU2236285917.USD"],"gpt_icon":0},{"id":"2603666888","title":"和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2603666888","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603666888?lang=zh_cn&edition=full","pubTime":"2026-01-14 12:11","pubTimestamp":1768363890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，公司今日宣布SACHI III期研究的结果于《柳叶刀 》发表。SACHI是一项赛沃替尼和奥希替尼的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体酪氨酸激酶抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。中国医学科学院肿瘤医院的王洁教授亦为SACHI 研究的联合主要研究者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4588","BK4007","BK1191","00013","BK4531","HCM","BK4585","BK1587","BK1588","BK4134"],"gpt_icon":0},{"id":"2601878841","title":"和黄医药(00013)宣布索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的 ESLIM-02中国研究的III期阶段取得阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2601878841","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601878841?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:03","pubTimestamp":1767744211,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血成人患者的ESLIM-02研究的III期注册阶段已达到第5至 24周治疗期间持久血红蛋白应答这一主要终点。ESLIM-02研究的完整数据将提交于近期的学术会议上发表。和黄医药计划于2026年上半年向中国国家药品监督管理局提交索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的新药上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4531","BK1587","BK1588","BK4588","III","BK4585","BK4007","HCM","00013","BK4134"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.0592},{"period":"1month","weight":-0.0997},{"period":"3month","weight":-0.0019},{"period":"6month","weight":0.1802},{"period":"1year","weight":0.6375},{"period":"ytd","weight":-0.0934}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.008931},{"month":3,"riseRate":0.333333,"avgChangeRate":0.043359},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.008159},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.028576},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}